Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein

Journal of General Virology

Volumn 82, Issue 7, 2001, Pages 1737-1747

  Vignuzzi, M ^a   Gerbaud, S ^a   van der Werf, S ^a   Escriou, N ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; PLASMID DNA; STRUCTURAL PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS NUCLEOPROTEIN; VIRUS RNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG HALF LIFE; DRUG SYNTHESIS; GENETIC TRANSFECTION; H2 SYSTEM; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPRECIPITATION; IN VITRO STUDY; INFLUENZA VIRUS A; LUNG; MOUSE; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; RNA REPLICATION; SEMLIKI FOREST ALPHAVIRUS; VIRUS LOAD; VIRUS STRAIN;

ALPHAVIRUS; ANIMALIA; INFLUENZA A VIRUS; INFLUENZA VIRUS; POLIOVIRUS; RABBIT FIBROMA VIRUS; RNA VIRUSES; SEMLIKI FOREST VIRUS;

EID: 0034959976     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-82-7-1737     Document Type: Article

References (50)

1. + T cells
2. Characterization of poliovirus replicons encoding carcinoembryonic antigen
3. DNA immunization of newborn mice with a plasmid-expressing nucleoprotein of influenza virus
4. Expression of human immunodeficiency virus type 1 (HIV-1) Gag, Pol, and Env proteins from chimeric HIV-1-poliovirus minireplicons
5. Characterization of a messenger RNA polynucleotide vaccine vector
6. In vivo priming by DNA injection occurs predominantly by antigen transfer
7. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal, and cellular immunity
8. Protection against homologous influenza challenge by genetic immunization with SFV RNA encoding Flu HA
9. MHC I-dependent antigen presentation is inhibited by poliovirus protein 3A
10. Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A
11. Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haemagglutinin or nucleoprotein of influenza virus
12. Cytotoxic T cell response to Mengo virus in mice: Effector cell phenotype and target proteins
13. Alphavirus-based expression vectors: Strategies and applications
14. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice
15. Determinants of substrate recognition by poliovirus 2A proteinase
16. Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants
17. AIDS virus Env protein expressed from a recombinant vaccinia virus
18. Assembly of influenza ribonucleoprotein in vitro using recombinant nucleoprotein
19. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge
20. DNA and RNA-based vaccines: Principles, progress and prospects
21. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon
22. Cytotoxic T-cell immunity to influenza
23. Antigenic drift of influenza A (H3N2) virus in a persistently infected immunocompromised host is similar to that occurring in the community
24. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen
25. Role of myristoylation of poliovirus capsid protein VP4 as determined by site-directed mutagenesis of its N-terminal sequence
26. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA
27. Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins
28. Potential DNA vaccine integration into host cell genome
29. Protection against lethal viral infection by vaccination with nonimmunodominant peptides
30. Influenza A virus - A model for viral antigen presentation to cytotoxic T lymphocytes
31. A poliovirus replicon containing the chloramphenicol acetyltransferase gene can be used to study the replication and encapsidation of poliovirus RNA
32. Immunization of mice with poliovirus replicons expressing the C-fragment of tetanus toxin protects against lethal challenge with tetanus toxin
33. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization
34. Antigenic and genetic variation in influenza A (H1N1) virus isolates recovered from a persistently infected immunodeficient child
35. Immuno-stimulatory DNA sequences necessary for effective intradermal gene immunization
36. Characterization and immunological properties of influenza A virus nucleoprotein (NP): Cell-associated NP isolated from infected cells or viral NP expressed by vaccinia recombinant virus do not confer protection
37. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo
38. + T cells is inefficient in the absence of B cells
39. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice
40. and others Heterologous protection against influenza by injection of DNA encoding a viral protein
41. + T cells against influenza virus induced by vaccination with nucleoprotein DNA
42. Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes
43. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens
44. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle
45. Reconstitution of influenza virus RNA-nucleoprotein complexes structurally resembling native viral ribonucleoprotein cores
46. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes
47. Cancer therapy using a self-replicating RNA vaccine
48. Self-replicating Semliki Forest virus RNA as recombinant vaccine
49. Generation of cytotoxic and humoral immune responses by non-replicative recombinant Semliki Forest virus